Edition:
United Kingdom

Abeona Therapeutics Inc (ABEO.OQ)

ABEO.OQ on NASDAQ Stock Exchange Capital Market

13.25USD
17 Aug 2018
Change (% chg)

$-0.45 (-3.28%)
Prev Close
$13.70
Open
$13.85
Day's High
$14.25
Day's Low
$13.00
Volume
155,641
Avg. Vol
202,705
52-wk High
$22.70
52-wk Low
$7.50

Chart for

About

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin... (more)

Overall

Beta: 2.29
Market Cap(Mil.): $713.08
Shares Outstanding(Mil.): 40.29
Dividend: --
Yield (%): --

Financials

  ABEO.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -0.60 -- --
ROI: -29.33 1.78 14.61
ROE: -30.75 3.28 16.33

BRIEF-Abeona Announces FDA Grants Rmat Designation To ABO-102 Gene Therapy In MPS Iiia

* ABEONA ANNOUNCES FDA GRANTS RMAT DESIGNATION TO ABO-102 GENE THERAPY IN MPS IIIA

23 Apr 2018

BRIEF-Abeona Therapeutics Receives Orphan Drug Designation In The European Union For ABO-202 Gene Therapy Program In Batten Disease

* ABEONA THERAPEUTICS RECEIVES ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR ABO-202 GENE THERAPY PROGRAM IN BATTEN DISEASE Source text for Eikon: Further company coverage:

20 Apr 2018

BRIEF-Abeona Therapeutics Appoints Carsten Thiel, Ph.D., As Chief Executive Officer

* ABEONA THERAPEUTICS APPOINTS CARSTEN THIEL, PH.D., AS CHIEF EXECUTIVE OFFICER

02 Apr 2018

BRIEF-Abeona Therapeutics Appoints Carsten Thiel As Chief Executive Officer

* TIMOTHY J. MILLER WILL REMAIN PRESIDENT AND ASSUME POSITION OF CHIEF SCIENTIFIC OFFICER Source text for Eikon: Further company coverage:

02 Apr 2018

BRIEF-Abeona Therapeutics Reports Q4 Loss Per Share $0.19

* ABEONA THERAPEUTICS REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

16 Mar 2018

BRIEF-Abeona Receives FDA Rare Pediatric Disease Designation For ABO-202 Gene Therapy Program In CLN1 Disease

* ABEONA THERAPEUTICS RECEIVES FDA RARE PEDIATRIC DISEASE DESIGNATION FOR ABO-202 GENE THERAPY PROGRAM IN CLN1 DISEASE

15 Mar 2018

Earnings vs. Estimates